The recipient of a master's degree in accounting from SUNY at Buffalo, Timothy "Tim" Maleck is a financial associate based in New York City. Outside of his professional responsibilities, Timothy Maleck enjoys a variety of athletic pursuits, including hockey. Arguably the world's best hockey player, Connor McDavid put himself into the conversation last season by winning the National Hockey League's (NHL) Hart Trophy, which is awarded annually to the league's most valuable player. The 20-year-old Edmonton Oilers center led the league in scoring with 100 points in 82 games and was the third-youngest player in league history to win the award. Additionally, he won the Ted Lindsay Award, which is given to the most outstanding player based on votes from his peers.McDavid received 147 of a possible 167 first-place votes for the Hart Trophy and finished ahead Sidney Crosby and Sergei Bobrovsky, who had 14 and four first-place votes respectively. The third-year pro appears poised to potentially repeat as Hart Trophy winner in 2017-18; in the Oilers' first game of the season against the Calgary Flames, McDavid scored three goals for his second career hat trick.
Based in New York City, Timothy (Tim) Maleck maintains a well-established presence as a financial analyst. A member of the Delta Sigma Pi co-ed professional business fraternity, Timothy Maleck also participates in fundraising events for cancer such as Relay for Life and Cycle for Survival. Established a decade ago, Cycle for Survival has a unique focus on rare cancers and has raised more than $140 million toward more than 100 research projects and clinical trials undertaken by the Memorial Sloan Kettering (MSK) Cancer Center. An example of one of MSK’s current projects is the development of a mass spec workflow that will provide increased sensitivity beyond conventional measures. The focus is on the measurement of biological sample peptides at the zeptomolar-concentration level. Results thus far are promising and although the single-molecule detection level has not been reached, detection is within the “hundreds of molecules” range. The end result is that quantitative measurements of profile pathways within patient samples is becoming more accurate. In particular, it addresses those cancers for which only small patient samples exist and there are not good antibodies to detect.
